Seeking Alpha
 

Uroplasty, Inc (UPI)

- NASDAQ
  • Fri, Jan. 23, 6:39 AM
    • Uroplasty (UPI -3.1%) FQ3 results: Revenues: $6.7M (+4.7%); Gross Profit: $5.9M (+5.4%); R&D Expense: $0.7M (+40.0%); S&M: $5M (+11.1%); Net Loss: ($2.1M) (-200.0%); Loss Per Share: ($0.10) (-233.3%); Quick Assets: $8.7M (-28.1%); CF Ops: ($3.2M) (-39.1%).
    • No guidance given.
    | Comment!
  • Thu, Jan. 22, 4:03 PM
    • Uroplasty (NASDAQ:UPI): FQ3 EPS of -$0.06 misses by $0.02.
    • Revenue of $6.7M (+4.7% Y/Y) misses by $0.09M.
    • Press Release
    | Comment!
  • Oct. 24, 2014, 9:04 AM
    • Uroplasty (UPI +2.9%) FQ2 results: Revenues: $6.5M (+12.1%); COGS: $0.8M (+14.3%); R&D Expense: $0.7M (+75.0%); SG&A: $6.1M (-9.0%); Net Loss: ($1.1M) (+42.1%); Loss Per Share: ($0.05) (+44.4%); Quick Assets: $9.5M (+9.2%); CF Ops: ($2.5M) (-13.6%).
    • No guidance given.
    | Comment!
  • Oct. 23, 2014, 4:46 PM
    • Uroplasty (NASDAQ:UPI): FQ2 EPS of -$0.05 beats by $0.02.
    • Revenue of $6.45M (+7.9% Y/Y) beats by $0.02M.
    • Press Release
    | Comment!
  • Oct. 9, 2014, 1:57 PM
    • Uroplasty (UPI -3.2%) will report fiscal Q2 results on October 23 after the close. The conference call will begin at 4:30 pm ET.
    • Consensus view is a loss of ($0.07) on revenues of $6.4M.
    | Comment!
  • Jul. 24, 2014, 4:35 PM
    • Uroplasty (NASDAQ:UPI): FQ1 EPS of -$0.10 misses by $0.05.
    • Revenue of $6.38M (+9.2% Y/Y) misses by $0.03M.
    • Press Release
    | Comment!
  • May. 15, 2014, 5:19 PM
    • Uroplasty (UPI): FQ4 EPS of -$0.05 misses by $0.01.
    • Revenue of $6.36M (+15% Y/Y) misses by $0.02M.
    • Press Release
    | 1 Comment
  • Oct. 24, 2013, 6:53 PM
    • Uroplasty (UPI): FQ2 EPS of -$0.09 misses by $0.04.
    • Revenue of $5.98M misses by $0.11M. (PR)
    | Comment!
  • Aug. 2, 2013, 3:18 PM
    • Uroplasty (UPI +17%) pops today after saying Medicare administrative contractor Novitas Solutions has expanded coverage for posterior tibial nerve stimulation using the company's Urgent PC neuromodulation system to treat overactive bladder and associated symptoms.
    • The increased coverage includes additional diagnostic codes as well as expansion of on-going therapy from 12 months to up to two years.
    • The company also reported FQ1 earnings last night that largely trailed analysts forecasts. (PR)
    | Comment!
  • Aug. 1, 2013, 7:01 PM
    • Uroplasty (UPI): FQ1 EPS of -$0.08 misses by $0.03.
    • Revenue of $5.84M beats by $0.13M. (PR)
    | Comment!
  • May. 30, 2013, 7:45 PM
    More on Uroplasty (UPI): Q4 misses across the board as total sales slipped 1% year over year. U.S. sales increased 2%, driven by an 11% increase in sales of the Urgent(R) PC Neuromodulation System, but global sales declined 1% to $5.5M. Additionally, the company said that Wisconsin Physicians Services, a Medicare Administrative Contractor providing benefits to approximately 8.7M Medicare beneficiaries in nine Midwestern states, will begin coverage for its Posterior Tibial Nerve Stimulation device as a treatment for overactive bladders and associated symptoms starting June 1. Shares +9.8% AH.
    | Comment!
  • May. 30, 2013, 4:50 PM
    Uroplasty (UPI): FQ4 EPS of -$0.05 misses by $0.01. Revenue of $5.54M misses by $0.05M. (PR)
    | Comment!
  • Jan. 24, 2013, 6:18 PM
    Uroplasty (UPI): FQ3 EPS of -$0.03 beats by $0.01. (PR)
    | Comment!
  • May. 25, 2012, 10:27 AM
    Uroplasty (UPI +9.6%) pops after its FQ4 results beat estimates on narrower losses. Global sales increased 39% Y/Y, while sales in the U.S. grew by 63%. The higher U.S. numbers were driven by a 79% increase in sales of its Urgent PC Neuromodulation System, and a 53% jump in sales of its Macroplastique. Separately, JMP Securities upgraded the shares to Outperform on the back of the better-than-anticipated report.
    | Comment!
Visit Seeking Alpha's
UPI vs. ETF Alternatives
Company Description
Uroplasty Inc a medical device company. It develops, manufactures and markets innovative, proprietary products for the treatment of voiding dysfunctions.